Rash Rates with EGFR Inhibitors: Meta-Analysis

Abstract

Introduction: Currently marketed epidermal growth factor receptor inhibitors (EGFRIS) have been associated with high rates of dermatologic toxicity. Methods: We formally reviewed the literature at MEDLINE and EMBASE. Additional searches were conducted using Internet search engines. Studies were eligible if they were randomized controlled clinical trials of egfris, specifically cetuximab and panitumumab, in which at least one arm consisted of a non-egfri treatment and rash safety data were reported. The random effects method was used to pool differences in incident rash rates. Results are summarized as differences in incident rash (EGFRIS therapy rate minus the non-EGFRIS therapy rate) with corresponding 95% confidence intervals (CIS) for all severity grades of rash and for grades 3 and 4 rash. Results: Sixteen studies met the initial inclusion criteria of randomized controlled trials comparing EGFRIS with non-EGFRIS therapy. Seven publications that provided information on all severity grades of rash were found to have an overall difference in incident rash rate of 0.74 (95% CI: 0.68 to 0.81; p < 0.01). Thirteen studies that reported the incidence of grades 3 and 4 rash showed an overall difference in the incident rash rate of 0.12 (95% CI: 0.09 to 0.14; p < 0.01) between EGFRIS and non-EGFRIS therapy. Sensitivity analyses showed that the results were generally robust, but sensitive to small samples. Conclusions: Results quantify the difference in rash rates between EGFRIS and non-EGFRIS therapy.

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

“…The total number of side effects and the intensity of specific toxicities, most notably fatigue, insomnia, nausea, vomiting and diarrhea, have been shown to markedly affect patient satisfaction with HRQoL [14-17]. The specific effect of other toxicities, such as dermatologic toxicities, on patient satisfaction with HRQoL is less well understood although they are known to occur with frequency in some treatments [18,19]. …”

The challenge of managing a cetuximab rash

“…Most of the rashes were lower than grade 3, and the drug was either dose-reduced or temporarily held, but it was not generally discontinued. 6 Of note is that in a nonselected survey of medical oncologists who were prescribing cetuximab, 76% reported holding the drug owing to rash severity, 60% reported dose reductions for a drug rash, and 32% reported changing the drug because of rash severity. 7 In the initial pharmaceutical registration trial, 76% to…”

Integrating Patient-Reported Measures into Routine Cancer Care: Cancer Patients’ and Clinicians’ Perceptions of Acceptability and Value

“…The study team also included headache, cough, rash, and urine leakage – given their moderate prevalence and effects on quality of life. 34 – 35 Quality of life was included as a domain – given its relevance for prognosis 36 and importance to patients. Finally, the research team felt it was important to give patients an opportunity to “set an agenda” for what they would like to discuss with their clinician to better personalize care.…”